Answers by TheMediTary.Com - Last updated: 13-Jul-2023
Opdivo is approved to treat advanced or metastatic urothelial cancer, the most common type of bladder cancer, in adults whose disease has progressed during, following, or within 12 months of first-line or adjuvant platinum-containing chemotherapy. Approximately 50% of patients with bladder cancer do not respond to their first course of chemotherapy, and only 10 to 15% of those respond to second-line chemotherapy, and Opdivo represents another treatment option for these people. Opdivo may also be used to treat adults with urothelial carcinoma that has a high risk of returning despite surgery.